Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial-Reference-Cited by-同舟云学术

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

Published:2022-06 Issue: Volume:48 Page:101432
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Fennell Dean A.^ORCID,Porter Catharine,Lester Jason,Danson Sarah,Taylor Paul,Sheaff Michael,Rudd Robin M,Gaba Aarti,Busacca Sara,Nixon Lisette^ORCID,Gardner Georgina,Darlison Liz,Poile Charlotte,Richards Cathy,Jordan Peter-Wells,Griffiths Gareth,Casbard Angela

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

2. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma;Stebbing;Lung Cancer,2009

3. Randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma;Kindler;J Thorac Oncol,2017

4. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial;Popat;Ann Oncol,2019

5. BRCA1/MAD2L1 deficiency disrupts the spindle assembly checkpoint to confer vinorelbine resistance in mesothelioma;Busacca;Mol Cancer Ther,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights;Open Respiratory Archives;2024-07

2. Contemporary management of mesothelioma;Breathe;2024-06

3. Monoterpene indole alkaloids with anticancer activity from Tabernaemontana species;Phytochemistry Reviews;2024-04-27

4. Consensus Guideline for the Management of Patients with Peritoneal Mesothelioma;2024-04-13

5. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund;Tumori Journal;2024-02-19